Bli medlem
Bli medlem

Du är här


Nuevolution: Redeye: Nuevolution pushing the envelope

Nuevolution has had a busy start of the year with a lot of progress.
The development of Chemetics continues to push boundaries with the
successful completion of a 40 trillion-member library, likely the
world's largest. The pipeline programs are progressing. ROR?t inverse
agonist are under development by Almirall and we expect initiation of
Phase I by early 2018, while other indications are being pursued by
NUE. The Amgen collaboration have been showing promising signs with
two projects identified and progressed. Somewhat higher costs than
previous estimates are outweighed by a lower the weighted average
cost of capital (WACC), resulting in a slightly higher fair value

Read more and download the Research Update by Mathias Spinnars at:

Become a member at Redeye to access the latest research on Life
Science and Tech companies.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.